Saturday, 20 April 2024
Cyclacel Pharmaceuticals Inc.
11:07 | 5/3/18
Collins Courier
Let's take a quick look at how the price of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) is currently trading in comparison to some of its simple moving averages.
more»
01:11 | 14/2/18
MoneyMakingArticles
Cyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) had a decrease of 20.52% in short interest. CYCC's SI was 628,400 shares in February as released by FINRA.
more»
01:00 | 7/2/18
GlobeNewswire
BERKELEY HEIGHTS, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage ...
more»
06:48 | 6/2/18
Post Analyst
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) recently had a low trading volume day. The volume for the company on 02-Feb-18 was recorded to be 0.57 million contracts.
more»
01:33 | 25/1/18
StockNewsJournal
Dividends is a reward scheme, that a company presents to its shareholders. There can be various forms of dividends, such as cash payment, stocks or any other form.
more»
01:00 | 25/1/18
GlobeNewswire
BERKELEY HEIGHTS, N.J., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage ...
more»
04:11 | 18/1/18
The Ledger Gazette
Cyclacel Pharmaceuticals logo Cyclacel Pharmaceuticals Inc (NASDAQ:CYCCP) declared a quarterly dividend on Monday, January 8th, Wall Street Journal reports.
more»
02:30 | 6/1/18
Post Analyst
VRX's mean recommendation on Reuter's scale presents no change from 2.95 thirty days ago to 2.95 now, which indicates a hold consensus from the analyst community.
more»
10:33 | 31/12/17
The Herald
The main US indices ended Friday's session weaker, as US economic growth cooled to the slowest pace in three years in the first quarter and geopolitical concerns reemerged.
more»
05:07 | 29/12/17
Analyst Journal
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) tinted loss of -0.57% (-0.01 points) to US$1.75. The volume of 0.24 Million shares climbed down over an trading activity of 693.08 Million shares.
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |